118 related articles for article (PubMed ID: 18996007)
1. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Jones CD; Andrews DM; Barker AJ; Blades K; Daunt P; East S; Geh C; Graham MA; Johnson KM; Loddick SA; McFarland HM; McGregor A; Moss L; Rudge DA; Simpson PB; Swain ML; Tam KY; Tucker JA; Walker M
Bioorg Med Chem Lett; 2008 Dec; 18(24):6369-73. PubMed ID: 18996007
[TBL] [Abstract][Full Text] [Related]
2. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Jones CD; Andrews DM; Barker AJ; Blades K; Byth KF; Finlay MR; Geh C; Green CP; Johannsen M; Walker M; Weir HM
Bioorg Med Chem Lett; 2008 Dec; 18(24):6486-9. PubMed ID: 18986805
[TBL] [Abstract][Full Text] [Related]
3. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W; Brigance RP; Chao HJ; Fura A; Harrity T; Marcinkeviciene J; O'Connor SP; Tamura JK; Xie D; Zhang Y; Klei HE; Kish K; Weigelt CA; Turdi H; Wang A; Zahler R; Kirby MS; Hamann LG
J Med Chem; 2010 Aug; 53(15):5620-8. PubMed ID: 20684603
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of PDK1 inhibitors.
Poulsen A; Blanchard S; Soh CK; Lee C; Williams M; Wang H; Dymock B
Bioorg Med Chem Lett; 2012 Jan; 22(1):305-7. PubMed ID: 22119465
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
9. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
10. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
Ellis JM; Altman MD; Bass A; Butcher JW; Byford AJ; Donofrio A; Galloway S; Haidle AM; Jewell J; Kelly N; Leccese EK; Lee S; Maddess M; Miller JR; Moy LY; Osimboni E; Otte RD; Reddy MV; Spencer K; Sun B; Vincent SH; Ward GJ; Woo GH; Yang C; Houshyar H; Northrup AB
J Med Chem; 2015 Feb; 58(4):1929-39. PubMed ID: 25625541
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
Blake JF; Gaudino JJ; De Meese J; Mohr P; Chicarelli M; Tian H; Garrey R; Thomas A; Siedem CS; Welch MB; Kolakowski G; Kaus R; Burkard M; Martinson M; Chen H; Dean B; Dudley DA; Gould SE; Pacheco P; Shahidi-Latham S; Wang W; West K; Yin J; Moffat J; Schwarz JB
Bioorg Med Chem Lett; 2014 Jun; 24(12):2635-9. PubMed ID: 24813737
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
Kawahata W; Asami T; Irie T; Sawa M
Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
[TBL] [Abstract][Full Text] [Related]
14. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
18. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]